Locations:
October 22, 2018/Cancer/Research

Which Breast Reconstruction Technique Is Best for Patients Undergoing Post-Mastectomy Radiation Therapy?

10-year outcomes favor autologous over implant

rad-treatment_650x450

Radiation therapy and breast reconstruction after mastectomy don’t always go well together. Rates of infection, dehiscence, skin and/or flap necrosis, and hematoma are higher in patients that undergo reconstruction and have post-mastectomy radiation therapy. In those patients that have reconstruction with a tissue expander/implant (TE/I), radiation is associated with higher rates of implant extrusion, leak or capsular contracture, while those that have autologous reconstruction (AR) are at risk for hernias as well.

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

Toxicity profiles vary by technique and timing, and data currently available in the literature provide little guidance on determining the optimal treatment approach, says Chirag Shah, MD, Director of Clinical Research and Breast Radiation Oncology in Cleveland Clinic’s Department of Radiation Oncology.

In response, Dr. Shah and colleagues at Cleveland Clinic recently compared rates of complications in patients who had post-mastectomy radiation therapy both before and after AR or TE/I.

“We suspected that radiation to a TE/I, regardless of timing, would portend worse outcomes,” says Dr. Shah. “Our study confirmed this. For patients requiring radiation after mastectomy, AR was associated with fewer trips back to the operating room for complications and fewer reconstruction failures.”

Results of this study will be shared in an oral presentation at the 2018 ASTRO Annual Meeting in San Antonio.

Comparing techniques and timing

The study included 230 patients that had 233 breast reconstructions. The patients had either AR or TE/I, either before or after radiation therapy, between 2000 and 2008. Median follow-up was 7.6 years. Age, BMI, and rates of active smoking, diabetes and hypertension were similar among the groups. Reconstruction was performed at the time of mastectomy, before radiation therapy, in 81 percent of patients.

Overall, rates of reconstruction failure (resulting in converting to another reconstruction technique or a flat chest wall) and complications requiring re-operation were significantly higher with TE/I as compared to AR (Table).

Advertisement

Table listing rates of reconstruction failure and complications requiring re-operation.

On multivariate analysis, the most significant predictors of complications requiring re-operation were:

  • TE/I (Odds Ratio 2.4; P = 0.007).
  • BMI ≥ 30 (Odds Ratio 3.4; P = 0.002).
  • Active smoking (Odds Ratio 2.7; P = 0.002).

The only significant predictor of reconstruction failure was TE/I (Odds Ratio 5.4; P < 0.001).

However, the rate of failure was not significantly different between the four groups when wound infection was excluded (P = 0.156).

Most complications requiring re-operation occurred within the first two years following treatment, but reconstruction failure occurred up to 10 years after reconstruction.

Rethinking the paradigm

“Many patients undergoing mastectomy get expanders and/or implants whether or not they have radiation therapy,” says Dr. Shah. “We may need to rethink that paradigm.”

These findings indicate that radiation therapy in patients with AR results in fewer complications and reconstruction failures than radiation therapy in patients with TE/I. Yet risk of failure with TE/I can be reduced by minimizing risk of infection.

Radiation oncologists should discuss treatment options in a multidisciplinary, collaborative group with breast surgeons and plastic surgeons, ensuring plans are in place for managing reconstruction risks, says Dr. Shah.

Advertisement

Related Articles

Dr. Arun Singh
October 21, 2026/Cancer

Preserving Vision in Uveal Melanoma (Podcast)

Understanding expanding treatment options and potential advances

Patient and doctor
October 9, 2026/Cancer/News & Insight

First Radioligand Therapy Approved for Metastatic Hormone-Sensitive Prostate Cancer

Adding 177Lu-PSMA-617 to ADT plus an ARPI cut the risk of radiographic progression or mortality by 28%

Woman running
October 7, 2026/Cancer/Patient Support

Pilot Project Aids Cancer Survivors in Achieving Healthy Weight and Reducing Recurrent Risk

New program will help patients improve fitness and manage weight after cancer treatment

Dr Keith McCrae
October 6, 2026/Cancer/Benign Hematology

How is ITP Therapy Evolving?

Cleveland Clinic hematologist highlights new guidelines and treatment advances in immune thrombocytopenia

Bone metastasis
October 5, 2026/Cancer/Innovations

Digital Platform Cuts Bone Metastasis Treatment Decision Time

NIMBLE replaces weekly tumor board delays with same-day multidisciplinary recommendations

Prostate cancer
October 2, 2026/Cancer/Radiation Oncology

ArteraAI Prostate Biomarker Accurate Across Diverse Populations

Cleveland Clinic study provides validation for the test, which combines AI and pathological data to predict outcomes in postoperative patients

Prostate cancer illustration
October 1, 2026/Cancer/Radiation Oncology

PSMA PET Scan-Guided LDR Brachytherapy Can Control Localized Prostate Cancer Recurrence

Advanced imaging technology catches metastases much earlier, allowing treatment with fewer side effects

Throat cancer
September 30, 2026/Cancer/Radiation Oncology

Same Cure Rate, Less Radiation in HPV-Associated Oral Cancer

Reduced radiation for lymph node areas reduces side effects

Ad